Revolutionizing maternal health through AI-driven placenta analysis
Pre-eclampsia is a serious and potentially deadly condition that can occur during pregnancy
Pre-eclampsia can lead to significant effects for a mother and baby such as insufficient oxygen, organ damage, and placental abruption. Without proper treatment, the condition can lead to death for the baby and/or the mother.
Incidence of pre-eclampsia has increased by 25% in the past 20 years
Additionally, hypertensive disorders in pregnancy have risen by 113.6% in the United States. Incidence is increasing due to population-level increases in risk factors such as pre-existing high blood pressure or kidney disease.
Pre-eclampsia is difficult to diagnose
16%
of maternal deaths in the United States are due to pre-eclampsia
10,500
babies in the United States die as a result of pre-eclampsia each year
5-8%
of pregnancies are affected by pre-eclampsia worldwide
Placenta AI is the only company addressing post-childbirth care with advanced AI technology promoting maternal well-being.
Placenta AI collaborates with global pathology leaders to
Provide efficient tissue analysis
AI Pathology integrates imaging with placenta pathology and machine learning to predict
future diseases without requiring additional invasive intervention or specimen collection.
Deliver essential health insights for moms and babies
Increased sampling of placentas allows health professionals to give more informed, life-saving care before, during, and after pregnancy.
Bridge medical expertise gaps
A current shortage of pathologists leaves critical analytical requests unmet. Our AI-driven solution effectively bridges this gap, ensuring that vital analyses are completed efficiently.
Analyze with speed
and accuracy
AI-driven analytics of placenta cells remove the variability of pathology interpretation and detects pre-eclampsia with greater accuracy and speed compared to traditional doctor-dependent methods.
Expertise
.jpg)
Eric Close
Founder/CEO
Early-stage venture know-how with five successful exits.
Jonathan Cagan
Founder/CTO
Industrial, start-up, and academic expertise.
Liron Pantanowitz
Founder/CMO
Pathology Informatics leader & innovator.
Philip LeDuc
Founder/CSO
Industrial, start-up, and academic expertise.
Placenta AI is leading innovation
In partnership with Carnegie Mellon University and the University of Pittsburgh, Placenta AI has made big waves in the fields of deep learning and AI detection.
Patents and Publications
Clymer, D., S. Kostidanov, J. Catov, L. Skvarca, L. Pantanowitz, J. Cagan, and P. R. LeDuc, “Decidual Vasculopathy Identification in Whole Slide Images using Multiresolution Hierarchical Convolutional Neural Networks,” The American Journal of Pathology, Vol. 190, No. 10, pp. 2111-2122, 2020.
Clymer, D., J. Cagan, P. R. LeDuc, “Method for Object Detection Using Hierarchical Deep Learning,” United States Patent No. 11,367,189, issued June 21, 2022.
Clymer, D., J. Cagan, P. R. LeDuc, L. Pantanowitz, J. Catov, “Method for Object Detection Using Hierarchical Deep Learning,” United States Patent 11,893,811, issued February 6, 2024.
Clymer, D., J. Cagan, P. R. LeDuc, “Method for Object Detection Using Hierarchical Deep Learning,” United States Patent Application No. 18/391820, submitted December 22, 2023.
Marletta S, Pantanowitz L, Santonicco N, et al. Application of Digital Imaging and Artificial Intelligence to Pathology of the Placenta. Pediatric and Developmental Pathology. 2023;26(1):5-12. doi:10.1177/10935266221137953
Placenta AI LLC
732 McDonald St.
Sewickley, PA 15143
© 2024 by Placenta AI LLC. All Rights Reserved.